HURN— AI Stock Forecast & Price Targets
Published 6/14/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live HURN price forecast →
Huron Consulting has been cut nearly in half from its early-2026 peak of ~$186 to $109, leaving shares at a depressed 10.7x forward P/E despite double-digit revenue growth and 23% ROE. Kronos forecasts and analyst targets ($184 consensus) point to mean-reversion upside, but Q1 free cash flow swung sharply negative and leverage has spiked, so the risk/reward favors selective accumulation rather than aggressive buying.
Stock is basing near 52w lows with RSI 46.9 and Kronos 1h forecast pointing to ~$120 (+10%). Tactical long entry on dips toward $105-107 with stop below $99.50 (under 52w low). Target $118-122 for a swing trade. Size small (1-2% portfolio) given negative Q1 FCF surprise still digesting. Invalidation: weekly close below $100.
Over 1-6 months, the setup hinges on Q2 earnings (next report ~early August) showing FCF normalization and confirmation that the RelateCare deal is accretive. If forward EPS of $10.22 holds, a re-rating to even 13-14x forward gets shares to $133-143, aligned with Kronos 4h forecast peak near $150 and Truist's $155 target. Expected return range: +20% to +35% base case, -15% bear if AI-disruption narrative deepens. What changes my mind: another quarter of negative FCF, or guidance cut.
Over 1-3 years, the secular question is whether Huron can pivot fast enough to AI-enabled managed services (RelateCare-style deals) before traditional advisory revenue is commoditized by AI tools. Healthcare and education verticals are sticky and regulated, providing some moat. If management executes, mid-teens EPS CAGR (consensus 9.3% long-term seems conservative) supports $160-200 over three years. Biggest structural risk: consulting industry margin compression as enterprises insource AI-augmented analysis — exactly what Aristotle Capital flagged. Debt/equity of 2.23x leaves little room for error.
Top line is healthy: Q1 2026 revenue of $451.8M (+11.8% Y/Y, record per Insider Monkey) extends a steady growth run, and TTM sales of $1.71B map to a modest 1.02x P/S. However, profitability is softening — Q1 gross margin compressed to 30.0% from 33.0% in Q4 2025, operating margin fell to 8.2% from 12.2%, and net margin slipped to 5.1%. Trailing EPS of $5.85 supports 18.7x P/E, but forward EPS of $10.22 implies a much cheaper 10.7x forward multiple and a reasonable 1.15 PEG. The balance sheet has deteriorated meaningfully: total debt jumped from $548M (Q4'25) to $887M (Q1'26), debt/equity is now 2.23x, and equity dropped from $529M to $397M — consistent with aggressive buybacks and/or M&A funding (RelateCare acquisition). Cash flow quality is the biggest red flag: Q1 operating cash flow was -$162M and FCF was -$174M, versus +$126M OCF in Q4'25. Some of this is seasonal working capital in consulting, but the magnitude warrants caution. ROE of 23.3% and ROIC of 8.3% remain solid, and current ratio of 2.22 provides liquidity cushion.
The weekly chart shows a textbook parabolic blowoff: HURN ran from ~$45 in 2022 to a $186.78 peak in early 2026, then crashed ~41% to the current $109.43, now sitting -24.7% below the 200-day SMA and -7.3% below the 50-day, with RSI at a neutral 46.9. The 1d Kronos forecast band is range-bound between roughly $120-$150 with a $127 endpoint — modest mean-reversion, not a V-recovery. The 4h forecast is more bullish, projecting a climb toward $175 by late summer, while the 1h chart shows near-term forecast at $120 vs spot $109, suggesting short-term upside of ~10%. The $100 level (52w low at $100.10) is critical support; failure there opens downside to the 2024 base in the $85-90 zone. Resistance stacks at $120 (forecast/SMA20 region), $130 (prior breakdown shelf), and $150 (gap fill). YTD performance of -36.7% and half-year -37.2% reflect heavy distribution, but Perf Month +5.8% and SMA20 +1.9% hint at early basing.
Signal: Truist maintained Buy but slashed its target from $240 to $155 (June 9), validating that even bulls have reset expectations downward. The RelateCare acquisition (June 4) adds AI-enabled healthcare managed services and is strategically coherent with Huron's healthcare consulting franchise — likely explains part of the debt build. Q1 results were genuinely strong (record revenue, guidance reaffirmed), yet the stock has not responded, suggesting the market is pricing in AI-disruption risk to traditional consulting (flagged explicitly in Aristotle Capital's letter and Simply Wall St coverage). Noise: the generic 'top services stocks' roundups add little. The Ophir Asset Management full exit (May 20) is a meaningful institutional vote of no-confidence and helps explain the supply pressure. Net: fundamentals OK, narrative damaged.
- RelateCare acquisition (June 2026) brings AI-enabled clinical/patient access solutions, deepening the high-margin healthcare managed services stack
- Q1 2026 record revenue of $443.7M before RBR (+12.1% Y/Y) with full-year guidance reaffirmed signals continued demand strength
- Forward EPS of $10.22 vs trailing $5.85 implies 75% earnings ramp baked into consensus — driven by margin recovery and buybacks
- Healthcare and Education segments benefit from secular spending on EHR/ERP modernization, AI/automation, and revenue cycle outsourcing
- Huron Research software suite and proprietary tech products create recurring revenue layer beyond pure advisory hours
- Q1 2026 free cash flow of -$174M (vs +$119M prior quarter) — even if seasonal, magnitude is concerning
- Total debt jumped 62% Q/Q to $887M; debt/equity now 2.23x with equity declining — limited cushion for missteps
- AI disruption thesis explicitly cited by Aristotle Capital as reason for underperformance; secular threat to billable-hour consulting model
- Ophir Asset Management's complete exit signals institutional confidence erosion; Inst Trans -6.21%
- Stock down 36.7% YTD and 41.4% from 52w high — technical damage takes quarters to repair; falling knife risk remains
- Gross margin compressed 300bps Q/Q to 30.0%; if this persists, the forward EPS bridge to $10.22 breaks
- Truist target cut from $240 to $155 (35% reduction) shows even bulls are recalibrating sharply lower
- Beta of 0.10 is misleadingly low — idiosyncratic drawdown risk is the real concern, not market correlation
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord